Screening for Autologous Blood Transfusions

Abstract

The ratio between the amount of hemoglobin in the mature erythrocyte population and the reticulocytes (RBCHb:RetHb ratio) has previously been suggested as a marker to screen for EPO-abuse. We speculated that the reinfusion of blood would lead to a marked increase in this ratio, making it a valuable parameter in the screening for autologous blood doping. Three bags of blood (∼201±11 g of Hb) were withdrawn from 16 males and stored at either −80°C (−80 T, n=8) or +4°C (+4 T, n=8) and reinfused 10 weeks or 4 weeks later, respectively. Seven subjects served as controls. Different erythrocyte parameters were measured on a hematological analyzer serially throughout and during a 4 week wash-out period. By using RBCHb:RetHb ratio cut-off limits of 145.7 (1:100) (‘suspicious’) and 182.9 (1:1 000) (‘positive’), 35.4% (−80 T) and 19.6% (+4 T) of all samples obtained during a 4 week wash-out period were identified as ‘suspicious’, and 18.8% (−80 T) and 4.3% (+4 T) as ‘positive’. In total, 7 out of 16 (43.8%) subjects had at least one sample exceeding 182.9. Compared to the currently used indirect parameters, the RBCHb:RetHb ratio is the best indicator of autologous blood doping after reinfusion, and the parameter could be used in a testing setting, once stability validation has been performed.

blood doping - hematological passport - doping - reticulocyte parameters

References

• 1 Transfusion alert: use of autologous blood. . National Heart, Lung, and Blood Institute Expert Panel on the use of autologous blood.  Transfusion. 1995;  35 703-711
• 2 Ashenden MJ, Lacoste A, Orhant E, Audran M, Sharpe K. Longitudinal variation of hemoglobin and reticulocytes in elite rowers.  Haematologica. 2004;  89 1403-1404
• 3 Ashenden MJ, Sharpe K, Damsgaard R, Jarvis L. Standardization of reticulocyte values in an antidoping context.  Am J Clin Pathol. 2004;  121 816-825
• 4 Berglund B, Hemmingson P. Effect of reinfusion of autologous blood on exercise performance in cross-country skiers.  Int J Sports Med. 1987;  8 231-233
• 5 Brugnara C, Zelmanovic D, Sorette M, Ballas SK, Platt O. Reticulocyte hemoglobin: an integrated parameter for evaluation of erythropoietic activity.  Am J Clin Pathol. 1997;  108 133-142
• 6 Buick FJ, Gledhill N, Froese AB, Spriet L, Meyers EC. Effect of induced erythrocythemia on aerobic work capacity.  J Appl Physiol. 1980;  48 636-642
• 7 Damsgaard R, Munch T, Morkeberg J, Mortensen SP, Gonzalez-Alonso J. Effects of blood withdrawal and reinfusion on biomarkers of erythropoiesis in humans: Implications for anti-doping strategies.  Haematologica. 2006;  91 1006-1008
• 8 Eichner ER. Blood doping: infusions, erythropoietin and artificial blood.  Sports Med. 2007;  37 389-391
• 9 Gore CJ, Parisotto R, Ashenden MJ, Stray-Gundersen J, Sharpe K, Hopkins W, Emslie KR, Howe C, Trout GJ, Kazlauskas R, Hahn AG. Second-generation blood tests to detect erythropoietin abuse by athletes.  Haematologica. 2003;  88 333-344
• 10 Malcovati L, Pascutto C, Cazzola M. Hematologic passport for athletes competing in endurance sports: a feasibility study.  Haematologica. 2003;  88 570-581
• 11 Morkeberg J, Saltin B, Belhage B, Damsgaard R. Blood profiles in elite cross-country skiers: a 6-year follow-up.  Scand J Med Sci Sports. 2008;  17 , [Epub ahead of print]
• 12 Pace N, Consolazio WV, Lozner EL. The effect of transfusions of red blood cells on the hypoxia tolerance of normal men.  Science. 1945;  102 589-591
• 13 Parisotto R, Gore CJ, Hahn AG, Ashenden MJ, Olds TS, Martin DT, Pyne DB, Gawthorn K, Brugnara C. Reticulocyte parameters as potential discriminators of recombinant human erythropoietin abuse in elite athletes.  Int J Sports Med. 2000;  21 471-479
• 14 Perry ES, Moore RH, Berger TA, Billups LC, Maybee DA, Salata KF, Lippert LE. In vitro and in vivo persistence of reticulocytes from donor red cells.  Transfusion. 1996;  36 318-321
• 15 Prommer N, Ehrmann U, Schmidt W, Steinacker JM, Radermacher P, Muth CM. Total haemoglobin mass and spleen contraction: a study on competitive apnea divers, non-diving athletes and untrained control subjects.  Eur J Appl Physiol. 2007;  101 753-759
• 16 Robinson N, Schattenberg L, Zorzoli M, Mangin P, Saugy M. Haematological analysis conducted at the departure of the Tour de France 2001.  Int J Sports Med. 2005;  26 200-207
• 17 Sharpe K, Ashenden MJ, Schumacher YO. A third generation approach to detect erythropoietin abuse in athletes.  Haematologica. 2006;  91 356-363
• 18 Sharpe K, Hopkins W, Emslie KR, Howe C, Trout GJ, Kazlauskas R, Ashenden MJ, Gore CJ, Parisotto R, Hahn AG. Development of reference ranges in elite athletes for markers of altered erythropoiesis.  Haematologica. 2002;  87 1248-1257
• 19 Valeri CR, Pivacek LE, Gray AD, Cassidy GP, Leavy ME, Dennis RC, Melaragno AJ, Niehoff J, Yeston N, Emerson CP. The safety and therapeutic effectiveness of human red cells stored at −80 degrees C for as long as 21 years.  Transfusion. 1989;  29 429-437
• 20 Valeri CR, Ragno G, Pivacek LE, Srey R, Hess JR, Lippert LE, Mettille F, Fahie R, O’Neill EM, Szymanski IO. A multicenter study of in vitro and in vivo values in human RBCs frozen with 40-percent (wt/vol) glycerol and stored after deglycerolization for 15 days at 4 degrees C in AS-3: assessment of RBC processing in the ACP 215.  Transfusion. 2001;  41 933-939

Correspondence